GSK re­ports its long-act­ing HIV PrEP tops Gilead­'s Tru­va­da — again

GSK sub­sidiary Vi­iV Health­care is notch­ing an­oth­er win on its score­card for cabote­gravir, the long-act­ing in­jectable it hopes can sup­plant Gilead’s dai­ly pill for HIV …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER